Austin Laue is a project manager for ParaGen Technologies. Previously, Austin worked for Lockheed Martin in finance and procurement roles. Austin earned his BSBA in Operations Management with an International Studies minor from The Ohio State University in 2016. He is from Rockford, IL and is passionate about fitness, food, water sports, coaching youth sports, and the NBA.
We would like to welcome Dawn to the RenovoDerm team! Dawn Cornett, Director of Market Development, is a former VP of Clinical Sales at Genadyne Biotechnologies with over 20 years of experience within the healthcare field. Dawn was responsible for launching Genadyne Biotechnologies national hospital division. For 9 years, Dawn was the Executive Director of a durable medical equipment company’s wound care division. Most notably, she was responsible for achieving a multi-million-dollar division within her first two years of a new product launch. Additionally, Dawn achieved a yearly growth of over 30% and oversaw the acquisition of Wrencare’s wound division to Lincare. While at Lincare, she again launched a successful national wound care program.
The ParaGen team recently participated in the fourth annual Innovation Hop at Rev1 Ventures. The event highlights growing Columbus startups and entrepreneurs, along with connecting those startups and entrepreneurs with their community.
Due to his expertise in the field of regenerative medicine, ParaGen's Jed Johnson was invited to attend the Regenerative Medicine Stakeholder's meeting taking place April 11-12, 2018 at the Bolger Center, Potomac, MD on behalf of the Clinical and Rehabilitative Medicine Research Program.
Jed Johnson, Ph.D. will discuss the pathways (and barriers) to bringing tissue engineered constructs to the bedside. He will explore the role of clinical collaborations, as well as the regulatory challenges with commercialization:
- Advantages of clinical collaborations: experience, facilities, patient populations
- Regulatory challenges: synthetic devices, cell-based devices, combination devices
- Funding challenges: animal studies, ISO 10993 biocompatibility studies, clinical trials
- Commercialization challenges: reimbursement, sales channels, manufacturing scale-up, cost
ParaGen medical director Dr. Cohen will be holding a health talk tomorrow on robotic assisted surgery! Check out Adena Health System’s website for more details.
Today, RenovoDerm announced that the U.S. Food and Drug Administration (FDA) has cleared its proprietary product, the Phoenix Wound Matrix, which is a wound care device that accelerates the body’s healing response, facilitates tissue growth and regeneration, reduces scar formation and enhances overall cosmesis.
The Phoenix Wound Matrix is a fully resorbable synthetic graft that closely mimics the extracellular matrix (ECM) found naturally in the body. This product will be used for the treatment of acute, chronic, and burn wounds, which continues to be a concern for both doctors and patients.
Ross Kayuha recently spoke at the Ikove Startup Nursery Showcase in New York City, representing ParaGen Technologies a featured company at the event.
The Vascular Genesis technical team were recently published in The Journal of Thoracic and Cardiovascular Surgery. Their paper in JTCVS focuses on virtual surgical planning, flow simulation, and three dimensional electrospinning of patient-specific grafts to optimize Fontan hemodynamics.